Get Articles Daily from StraightStocks - Enter Email Address


  • National Debt Clock


Entest Biomedical COPD Treatments (OTC:ENTB)

Source: http://feedproxy.google.com/~r/FavStocks/~3/JrKMLaZHZH8/
 Posted on Friday, November 6th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
Contributed by: Jay Garcilazo (http://favstocks.com) -

Entest Biomedical Inc (OTC:ENTB) announced that the Company’s unique treatments for Chronic Obstructive Pulmonary Disease also known as COPD, which is currently under development, can lead to substantial revenue opportunities in the near future. Entest Biomedical’s CEO and Chairman, David Koos stated that the current treatment for COPD is aimed at improving the quality of life of the patient and not curing the illness. Hence, Entest is working hard to reverse the damage from COPD.

Entest Biomedical Inc is a majority owned subsidiary of Bio-Matrix Scientific Group Inc. Currently, the Company is into the development of stem cell therapy treatments for Chronic Obstructive Pulmonary Disease (COPD), testing procedures for diabetes, immuno-therapies for cancer, stem cell research applications for other illnesses and diabetes. The Company also is involved with medical device development (including stem cell extraction instrumentation). Entest is also seeking grant funding in excess of $3 million to support its research and is applying for government development contracts. And over the next five years, Entest Biomedical has decided that they will spend US$170 billion for the treatment of COPD in the United States.

COPD is the 4th leading cause of death in the United States and is projected that in next ten years it will be the 3rd leading cause of death in the United States. It is also estimated that more than US$800 billion will be spent on the medical related costs to combat chronic obstructive pulmonary disease. David Koos also stated that they might soon come up with a photoceutical device to direct stem cells to targeted damaged lung tissue which may actually reverse the impact and effects of COPD.

Last 5 posts by Jay Garcilazo
About Jay Garcilazo (http://favstocks.com)
I grew up in Boca Raton, Florida. After graduating high school I enrolled at Florida State University where I studied Journalism and Political Science. It was around this time that I got a job in the healthcare industry, a job that would give me a lot of experience as I worked and moved up over the next four and a half years. This along with working for a hedge fund manager for years, were the greatest learning experiences of my life so far.

I have also been fortunate enough to have lived all over the country in, Austin, Texas, Queens, New York, Great Falls, Montana, Cleveland, Ohio, Chattanooga, Tennessee, Atlanta, Georgia, and all over the state of Florida. As well as living in many places I have traveled all over, been to all of the states except California (Had a layover at LAX once but I don’t think that counts), Oregon, and Hawaii. Traveled most of the Caribbean, I have also been to many destinations in Canada, and Mexico. I even did a stint through Europe. As well as traveling and living all over I have also worked in a great many industries. I have been employed in finance, healthcare, title, mortgage, travel, video game development, hospitality, and news industries.

Besides working for an investment company I have also done quite a bit of investing on my own, and through trial and error, learning from mistakes, and watching the news very closely I have made some decent money for myself.

Leave a Reply

Name

Email (kept private)

Website









No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.